Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a systematic review and meta-analysis of literature data
The aim of this meta-analysis was to ascertain whether sotrovimab was effective in reducing COVID-19 related hospitalization and mortality also in Omicron BA.2, BA.4 and BA.5 subvariants compared to other antivirals effective in index period. A systematic review and meta-analysis of Randomized Contr...
Saved in:
| Published in | Frontiers in immunology Vol. 15; p. 1295029 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Media S.A
2024
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The aim of this meta-analysis was to ascertain whether sotrovimab was effective in reducing COVID-19 related hospitalization and mortality also in Omicron BA.2, BA.4 and BA.5 subvariants compared to other antivirals effective in index period.
A systematic review and meta-analysis of Randomized Controlled Trials (RCTs) and observational studies comparing the efficacy of early treatment with sotrovimab compared to other early treatment effective in index period, antivirals or monoclonal antibodies (mAbs), in patients with COVID-19 during BA.2, BA.4, BA.5 waves, conducted in accordance with PRISMA guidelines. We searched MEDLINE, Google Scholar and the Cochrane Library. Mortality and hospitalization were defined as outcomes.
Four studies were included, allowing a meta-analysis of 8,041 patients. Meta-analysis showed no statistical difference between groups in hospitalization and mortality. Precisely, the RR of mortality showed no difference in the sotrovimab group compared to treatment with other drugs (OR 0.38, 95% CI 0.10-1.49, p<0.166). As regards the rate of hospitalization, no significant difference resulted between the patients treated with sotrovimab and those with other drugs (OR 1.66, 95% CI 0.41-6.66, p=0.477).
In conclusion, this meta-analysis showed no significant difference between sotrovimab or other antivirals in reducing COVID-19 evolution in patients with a high risk of progression, considering both hospitalization and mortality. |
|---|---|
| AbstractList | The aim of this meta-analysis was to ascertain whether sotrovimab was effective in reducing COVID-19 related hospitalization and mortality also in Omicron BA.2, BA.4 and BA.5 subvariants compared to other antivirals effective in index period.
A systematic review and meta-analysis of Randomized Controlled Trials (RCTs) and observational studies comparing the efficacy of early treatment with sotrovimab compared to other early treatment effective in index period, antivirals or monoclonal antibodies (mAbs), in patients with COVID-19 during BA.2, BA.4, BA.5 waves, conducted in accordance with PRISMA guidelines. We searched MEDLINE, Google Scholar and the Cochrane Library. Mortality and hospitalization were defined as outcomes.
Four studies were included, allowing a meta-analysis of 8,041 patients. Meta-analysis showed no statistical difference between groups in hospitalization and mortality. Precisely, the RR of mortality showed no difference in the sotrovimab group compared to treatment with other drugs (OR 0.38, 95% CI 0.10-1.49, p<0.166). As regards the rate of hospitalization, no significant difference resulted between the patients treated with sotrovimab and those with other drugs (OR 1.66, 95% CI 0.41-6.66, p=0.477).
In conclusion, this meta-analysis showed no significant difference between sotrovimab or other antivirals in reducing COVID-19 evolution in patients with a high risk of progression, considering both hospitalization and mortality. The aim of this meta-analysis was to ascertain whether sotrovimab was effective in reducing COVID-19 related hospitalization and mortality also in Omicron BA.2, BA.4 and BA.5 subvariants compared to other antivirals effective in index period.BackgroundThe aim of this meta-analysis was to ascertain whether sotrovimab was effective in reducing COVID-19 related hospitalization and mortality also in Omicron BA.2, BA.4 and BA.5 subvariants compared to other antivirals effective in index period.A systematic review and meta-analysis of Randomized Controlled Trials (RCTs) and observational studies comparing the efficacy of early treatment with sotrovimab compared to other early treatment effective in index period, antivirals or monoclonal antibodies (mAbs), in patients with COVID-19 during BA.2, BA.4, BA.5 waves, conducted in accordance with PRISMA guidelines. We searched MEDLINE, Google Scholar and the Cochrane Library. Mortality and hospitalization were defined as outcomes.MethodsA systematic review and meta-analysis of Randomized Controlled Trials (RCTs) and observational studies comparing the efficacy of early treatment with sotrovimab compared to other early treatment effective in index period, antivirals or monoclonal antibodies (mAbs), in patients with COVID-19 during BA.2, BA.4, BA.5 waves, conducted in accordance with PRISMA guidelines. We searched MEDLINE, Google Scholar and the Cochrane Library. Mortality and hospitalization were defined as outcomes.Four studies were included, allowing a meta-analysis of 8,041 patients. Meta-analysis showed no statistical difference between groups in hospitalization and mortality. Precisely, the RR of mortality showed no difference in the sotrovimab group compared to treatment with other drugs (OR 0.38, 95% CI 0.10-1.49, p<0.166). As regards the rate of hospitalization, no significant difference resulted between the patients treated with sotrovimab and those with other drugs (OR 1.66, 95% CI 0.41-6.66, p=0.477).ResultsFour studies were included, allowing a meta-analysis of 8,041 patients. Meta-analysis showed no statistical difference between groups in hospitalization and mortality. Precisely, the RR of mortality showed no difference in the sotrovimab group compared to treatment with other drugs (OR 0.38, 95% CI 0.10-1.49, p<0.166). As regards the rate of hospitalization, no significant difference resulted between the patients treated with sotrovimab and those with other drugs (OR 1.66, 95% CI 0.41-6.66, p=0.477).In conclusion, this meta-analysis showed no significant difference between sotrovimab or other antivirals in reducing COVID-19 evolution in patients with a high risk of progression, considering both hospitalization and mortality.InterpretationIn conclusion, this meta-analysis showed no significant difference between sotrovimab or other antivirals in reducing COVID-19 evolution in patients with a high risk of progression, considering both hospitalization and mortality. Background The aim of this meta-analysis was to ascertain whether sotrovimab was effective in reducing COVID-19 related hospitalization and mortality also in Omicron BA.2, BA.4 and BA.5 subvariants compared to other antivirals effective in index period. Methods A systematic review and meta-analysis of Randomized Controlled Trials (RCTs) and observational studies comparing the efficacy of early treatment with sotrovimab compared to other early treatment effective in index period, antivirals or monoclonal antibodies (mAbs), in patients with COVID-19 during BA.2, BA.4, BA.5 waves, conducted in accordance with PRISMA guidelines. We searched MEDLINE, Google Scholar and the Cochrane Library. Mortality and hospitalization were defined as outcomes. Results Four studies were included, allowing a meta-analysis of 8,041 patients. Meta-analysis showed no statistical difference between groups in hospitalization and mortality. Precisely, the RR of mortality showed no difference in the sotrovimab group compared to treatment with other drugs (OR 0.38, 95% CI 0.10-1.49, p<0.166). As regards the rate of hospitalization, no significant difference resulted between the patients treated with sotrovimab and those with other drugs (OR 1.66, 95% CI 0.41-6.66, p=0.477). Interpretation In conclusion, this meta-analysis showed no significant difference between sotrovimab or other antivirals in reducing COVID-19 evolution in patients with a high risk of progression, considering both hospitalization and mortality. BackgroundThe aim of this meta-analysis was to ascertain whether sotrovimab was effective in reducing COVID-19 related hospitalization and mortality also in Omicron BA.2, BA.4 and BA.5 subvariants compared to other antivirals effective in index period.MethodsA systematic review and meta-analysis of Randomized Controlled Trials (RCTs) and observational studies comparing the efficacy of early treatment with sotrovimab compared to other early treatment effective in index period, antivirals or monoclonal antibodies (mAbs), in patients with COVID-19 during BA.2, BA.4, BA.5 waves, conducted in accordance with PRISMA guidelines. We searched MEDLINE, Google Scholar and the Cochrane Library. Mortality and hospitalization were defined as outcomes.ResultsFour studies were included, allowing a meta-analysis of 8,041 patients. Meta-analysis showed no statistical difference between groups in hospitalization and mortality. Precisely, the RR of mortality showed no difference in the sotrovimab group compared to treatment with other drugs (OR 0.38, 95% CI 0.10-1.49, p<0.166). As regards the rate of hospitalization, no significant difference resulted between the patients treated with sotrovimab and those with other drugs (OR 1.66, 95% CI 0.41-6.66, p=0.477).InterpretationIn conclusion, this meta-analysis showed no significant difference between sotrovimab or other antivirals in reducing COVID-19 evolution in patients with a high risk of progression, considering both hospitalization and mortality. |
| Author | Coppola, Nicola Russo, Antonio Grimaldi, Pierantonio Pisaturo, Mariantonietta Onorato, Lorenzo |
| AuthorAffiliation | Department of Mental Health and Public Medicine - Infectious Disease Unit, University of Campania Luigi Vanvitelli , Naples , Italy |
| AuthorAffiliation_xml | – name: Department of Mental Health and Public Medicine - Infectious Disease Unit, University of Campania Luigi Vanvitelli , Naples , Italy |
| Author_xml | – sequence: 1 givenname: Antonio surname: Russo fullname: Russo, Antonio organization: Department of Mental Health and Public Medicine - Infectious Disease Unit, University of Campania Luigi Vanvitelli, Naples, Italy – sequence: 2 givenname: Pierantonio surname: Grimaldi fullname: Grimaldi, Pierantonio organization: Department of Mental Health and Public Medicine - Infectious Disease Unit, University of Campania Luigi Vanvitelli, Naples, Italy – sequence: 3 givenname: Mariantonietta surname: Pisaturo fullname: Pisaturo, Mariantonietta organization: Department of Mental Health and Public Medicine - Infectious Disease Unit, University of Campania Luigi Vanvitelli, Naples, Italy – sequence: 4 givenname: Lorenzo surname: Onorato fullname: Onorato, Lorenzo organization: Department of Mental Health and Public Medicine - Infectious Disease Unit, University of Campania Luigi Vanvitelli, Naples, Italy – sequence: 5 givenname: Nicola surname: Coppola fullname: Coppola, Nicola organization: Department of Mental Health and Public Medicine - Infectious Disease Unit, University of Campania Luigi Vanvitelli, Naples, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38352882$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVks9u1DAQxiNUREvpC3BAPnIgiz3OP3NBpSpQqRIXOFsTZ9K6SuLFdoL2eXhRnN2lan3wjGx_vxmNv9fZyeQmyrK3gm-kbNTH3o7jvAEOxUaAKjmoF9mZqKoilwDFyZP8NLsI4YGnVSgpZfkqO5WNLKFp4Cz7e9331qDZMdez4KJ3ix2xZW5ibrTGp_jlcgMf1r1gOHVrUrIwtwt6i1MMeyH6kBu35MCWsGEu3pNnhH7YsTXFraXwiSELuxBpxGgN87RY-rMnjhQxxwmHXbB73GBjEsXZE-sw4pvsZY9DoItjPM9-fb3-efU9v_3x7ebq8jY3BfCYC9FWqlJ9XRUce1PWJaiWSIDoe9O02BlUSplGcdVDTV3X1WkckKYiDKeulefZzYHbOXzQW58G4XfaodX7A-fvNPrU-0AaawEGQYpUpAAqFG_q1vC1al2oBhLr84G1nduROkNT9Dg8gz6_mey9vnOLFrypRF03ifD-SPDu90wh6tEGQ8OAE7k5aFBQlSAqUaWncHia_isET_1jHcH16ha9d4te3aKPbkmid087fJT894b8B1tYvqc |
| Cites_doi | 10.1136/bmj.l4898 10.1101/2021.03.09.434607 10.1016/0197-2456(86)90046-2 10.1136/bmjopen-2015-010983 10.1016/j.cell.2022.09.018 10.1186/s12879-022-07774-9 10.1056/NEJMoa2102685 10.1056/NEJMoa2108163 10.1038/s41591-022-01792-5 10.1056/NEJMoa2029849 10.1016/j.cell.2022.04.035 10.1186/1471-2288-14-45 10.3390/v15010071 10.1038/s41467-022-31615-7 10.3390/ijms24087099 10.1093/cid/ciad181 10.1136/bmj.b2535 10.1136/bmj-2022-071932 10.1016/j.cmi.2022.12.016 10.1111/tid.14007 10.1016/j.ijid.2023.03.030 10.1056/NEJMoa2107934 |
| ContentType | Journal Article |
| Copyright | Copyright © 2024 Russo, Grimaldi, Pisaturo, Onorato and Coppola. Copyright © 2024 Russo, Grimaldi, Pisaturo, Onorato and Coppola 2024 Russo, Grimaldi, Pisaturo, Onorato and Coppola |
| Copyright_xml | – notice: Copyright © 2024 Russo, Grimaldi, Pisaturo, Onorato and Coppola. – notice: Copyright © 2024 Russo, Grimaldi, Pisaturo, Onorato and Coppola 2024 Russo, Grimaldi, Pisaturo, Onorato and Coppola |
| DBID | NPM AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.3389/fimmu.2024.1295029 |
| DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1664-3224 |
| ExternalDocumentID | oai_doaj_org_article_a712ca23175242e49087bc0fc5774982 10_3389_fimmu_2024_1295029 38352882 |
| Genre | Systematic Review |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV DIK EBS EMOBN GROUPED_DOAJ GX1 HYE IAO IEA IHR IHW IPNFZ KQ8 M48 M~E NPM OK1 PGMZT RIG RNS RPM AAYXX CITATION 7X8 ITC 5PM |
| ID | FETCH-LOGICAL-c420t-11b6969f7640afc57529bee121ffc8badca999c8909f27eddd733320491c0edb3 |
| IEDL.DBID | RPM |
| ISSN | 1664-3224 |
| IngestDate | Fri Oct 04 12:45:24 EDT 2024 Tue Sep 17 21:29:54 EDT 2024 Sat Aug 17 04:14:36 EDT 2024 Thu Sep 26 18:51:11 EDT 2024 Sun Oct 13 10:29:57 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | COVID-19 mortality hospitalization early treatment monoclonal antibodies |
| Language | English |
| License | Copyright © 2024 Russo, Grimaldi, Pisaturo, Onorato and Coppola. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c420t-11b6969f7640afc57529bee121ffc8badca999c8909f27eddd733320491c0edb3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 Edited by: Valentina Mazzotta, National Institute for Infectious Diseases Lazzaro Spallanzani (IRCCS), Italy Ayman Al Jurdi, Massachusetts General Hospital and Harvard Medical School, United States Reviewed by: Stelvio Tonello, University of Eastern Piedmont, Italy |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10861778/ |
| PMID | 38352882 |
| PQID | 2926521616 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a712ca23175242e49087bc0fc5774982 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10861778 proquest_miscellaneous_2926521616 crossref_primary_10_3389_fimmu_2024_1295029 pubmed_primary_38352882 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-00-00 |
| PublicationDateYYYYMMDD | 2024-01-01 |
| PublicationDate_xml | – year: 2024 text: 2024-00-00 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in immunology |
| PublicationTitleAlternate | Front Immunol |
| PublicationYear | 2024 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Moher (B8) 2009; 339 Dougan (B22) 2021; 385 B25 B26 DerSimonian (B11) 1986; 7 Rizzi (B4) 2023; 24 Lo (B10) 2014; 14 Martin-Blondel (B18) 2023; 29 Gupta (B21) 2021; 385 Nevola (B24) 2023; 131 Case (B28) 2022; 13 Yamasoba (B2) 2022; 185 Bruel (B27) 2022; 28 Chen (B23) 2021; 384 Cathcart (B6) 2021 (B13) 2019 Zheng (B17) 2022; 379 B30 B31 Kimura (B1) 2022; 185 B14 Cheng (B12) 2016; 6 B3 De Vito (B15) 2022; 15 B5 B7 Weinreich (B20) 2021; 385 Mikulska (B29) 2023 Casutt (B19) 2023; 25 Sterne (B9) 2009; 366 Scaglione (B16) 2022; 22 |
| References_xml | – volume: 366 year: 2009 ident: B9 article-title: RoB 2: a revised tool for assessing risk of bias in randomised trials publication-title: BMJ doi: 10.1136/bmj.l4898 contributor: fullname: Sterne – year: 2021 ident: B6 article-title: The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2 publication-title: Hebner bioRxiv doi: 10.1101/2021.03.09.434607 contributor: fullname: Cathcart – volume: 7 year: 1986 ident: B11 article-title: Meta-analysis in clinical trials publication-title: Control Clin Trials doi: 10.1016/0197-2456(86)90046-2 contributor: fullname: DerSimonian – volume: 6 year: 2016 ident: B12 article-title: Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study publication-title: BMJ Open doi: 10.1136/bmjopen-2015-010983 contributor: fullname: Cheng – ident: B14 – volume: 185 start-page: 3992 year: 2022 ident: B1 article-title: Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5 publication-title: Cell doi: 10.1016/j.cell.2022.09.018 contributor: fullname: Kimura – ident: B3 – volume: 22 start-page: 793 year: 2022 ident: B16 article-title: Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study publication-title: BMC Infect Dis doi: 10.1186/s12879-022-07774-9 contributor: fullname: Scaglione – volume: 385 year: 2021 ident: B22 article-title: Bamlanivimab plus etesevimab in mild or moderate covid-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2102685 contributor: fullname: Dougan – volume: 385 year: 2021 ident: B20 article-title: REGEN-COV antibody combination and outcomes in outpatients with covid-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2108163 contributor: fullname: Weinreich – volume: 28 year: 2022 ident: B27 article-title: Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies publication-title: Nat Med doi: 10.1038/s41591-022-01792-5 contributor: fullname: Bruel – ident: B7 – ident: B5 – ident: B25 – volume: 384 year: 2021 ident: B23 article-title: SARS-CoV-2 neutralizing antibody LY-coV555 in outpatients with covid-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2029849 contributor: fullname: Chen – volume: 185 start-page: 2103 year: 2022 ident: B2 article-title: Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike publication-title: Cell doi: 10.1016/j.cell.2022.04.035 contributor: fullname: Yamasoba – volume-title: Stata Statistical Software: Release 16 year: 2019 ident: B13 – ident: B31 – volume: 14 year: 2014 ident: B10 article-title: Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments publication-title: BMC Med Res Methodol doi: 10.1186/1471-2288-14-45 contributor: fullname: Lo – volume: 15 year: 2022 ident: B15 article-title: Impact of early SARS-CoV-2 antiviral therapy on disease progression publication-title: Viruses doi: 10.3390/v15010071 contributor: fullname: De Vito – volume: 13 start-page: 3824 year: 2022 ident: B28 article-title: Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains publication-title: Nat Commun doi: 10.1038/s41467-022-31615-7 contributor: fullname: Case – volume: 24 year: 2023 ident: B4 article-title: COVID-19 biomarkers at the crossroad between patient stratification and targeted therapy: the role of validated and proposed parameters publication-title: Int J Mol Sci doi: 10.3390/ijms24087099 contributor: fullname: Rizzi – start-page: ciad181 year: 2023 ident: B29 article-title: Triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients publication-title: Clin Infect Dis doi: 10.1093/cid/ciad181 contributor: fullname: Mikulska – volume: 339 year: 2009 ident: B8 article-title: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement publication-title: BMJ doi: 10.1136/bmj.b2535 contributor: fullname: Moher – ident: B26 – volume: 379 year: 2022 ident: B17 article-title: Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform publication-title: BMJ. doi: 10.1136/bmj-2022-071932 contributor: fullname: Zheng – volume: 29 year: 2023 ident: B18 article-title: Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2022.12.016 contributor: fullname: Martin-Blondel – volume: 25 year: 2023 ident: B19 article-title: Outcomes of SARS-CoV-2 infection among lung transplant recipients: A single center retrospective study publication-title: Transpl Infect Dis doi: 10.1111/tid.14007 contributor: fullname: Casutt – volume: 131 year: 2023 ident: B24 article-title: Mortality and risk factors of vaccinated and unvaccinated frail patients with COVID-19 treated with anti-SARS-CoV-2 monoclonal antibodies: A real-world study publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2023.03.030 contributor: fullname: Nevola – ident: B30 – volume: 385 year: 2021 ident: B21 article-title: Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab publication-title: N Engl J Med doi: 10.1056/NEJMoa2107934 contributor: fullname: Gupta |
| SSID | ssj0000493335 |
| Score | 2.4156551 |
| SecondaryResourceType | review_article |
| Snippet | The aim of this meta-analysis was to ascertain whether sotrovimab was effective in reducing COVID-19 related hospitalization and mortality also in Omicron... Background The aim of this meta-analysis was to ascertain whether sotrovimab was effective in reducing COVID-19 related hospitalization and mortality also in... BackgroundThe aim of this meta-analysis was to ascertain whether sotrovimab was effective in reducing COVID-19 related hospitalization and mortality also in... |
| SourceID | doaj pubmedcentral proquest crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 1295029 |
| SubjectTerms | COVID-19 early treatment hospitalization Immunology monoclonal antibodies mortality |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEBUlUOil9LvbpkWF3lpvLFm2pN6SkhAK7amB3IQ-aUrXDlnvQn5P_2hmJGezWwq99OI1u7Ys5kk7b2TNG0Le14l53VhfMS9DJSyWeQkaJl7izqrkgKJjcvLXb93pmfhy3p5vlfrCPWFFHrgY7sBKxr3l6ObAm0R8TyWdr5NvgbhoVf59WbsVTP0svLdpmrZkyUAUpg_SxWKxgniQizm4uLbOnPLOE2XB_r-xzD83S255n5NH5OFEG-lh6e5jci_2T8j9Ukjy-in5fYxKENZf0yHR5TDiOsHCOjr0FLOOr-Dz6HDOP-JRUNsHPGnpcuXWECvjVph8IwS5lR_WFafr5Zzm3CwaUQGZljQtiKo_UUvv1J9pyXzJLS7iaCs7aZxgc782is0U96E-I2cnx98_n1ZT-YXKC16PFWOu051OshO1RXu3XLsYGWcpeeVs8BbYpVe61onLGEKQYHMOpme-jsE1z8leP_TxJaG1lzHqBK0kJeBKoCEiIopKCx14mpEPt1CYy6KyYSA6QeBMBs4gcGYCbkaOEK3NlaiQnb-AcWOmcWP-NW5m5N0t1gZmFL4msX0cVkvDNe-A1HSsm5EXBfvNoxokrArvVjujYqcvu7_0Fz-yajeWtGJSqlf_o_evyQO0SFkL2id749UqvgF2NLq3eSLcADDnDlI priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZKERIXxJsFiozEDbLEjjeOK6GqRa0qpHJipd4sP2lRN4FNdsX-Hv5oZ-LswqJy4JK3ncTfWP4m8XxDyJs8MqcK4zLmpM-EwTQvXkHHi9yaKlqg6BicfPa5PJ2KT-eT8x2yTnc0NGB7o2uH-aSm86vxzx-rA-jwH9DjhPH2fbyczRbg6nExhtFrknN1i9zmohBo8WcD3f-W2HBR9Dk3WVmKDGxZpDiaf1SzNVb1kv438dC_p1P-MT6d3Cf3BmJJD5MlPCA7oX5I7qRUk6tH5NcxakUYt6JNpG3T4ZeEmbG0qSnGJc9hfXQ45u9wKaipPW5MaLuwS_CmcbJMXxDaKnPNMuN02Y5pH71FA2ok0xTIBX73PjX0tz40TbExfY2z0JnMDCooWN3VRtOZ4kzVx2R6cvzl42k2JGjInOB5lzFmS1WqKEuRm-iA-XFlQ2Ccxegqa7wzwD9dpXIVuQzeewntzwEG5vLgbfGE7NZNHZ4RmjsZgopQS6wEXAlERQTr8lgpoTyPI_J2DYX-nnQ4NPgvCJzugdMInB6AG5EjRGtzJWpo9wea-Vc9dEltJOPOcCRQwFMC_gGVeEd4DylUxUfk9RprDX0Of6SYOjSLVnPFS6A9JStH5GnCfnOrAilthaWrLavYepbtM_XlRa_rjUmvmJTV8_961xfkLu6mz0IvyW43X4Q9IEqdfdVb_zXyxhG2 priority: 102 providerName: Scholars Portal |
| Title | Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a systematic review and meta-analysis of literature data |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38352882 https://www.proquest.com/docview/2926521616/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC10861778 https://doaj.org/article/a712ca23175242e49087bc0fc5774982 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLa2SUhcEL8pjMlI3CBt7LixzW2bNiakIg5M6i2yHRs6LcnUppX29_CP7j0n6VbEiYsTJbHj-LPl7znvfSbkYxqY05lxCXOyTITBbV5KDQMvcGtUsEDRMTh59j2_uBTf5tP5HsmHWJjotO_sYlxfV-N68Tv6Vt5UbjL4iU1-zE5xdyAmpZrsk32ZZQ9s9KuO82ZZNu0iZMAC05OwqKo12IJcjGF6m6aRT97PQlGs_18M829HyQczz_lT8qSnjPS4q9ozsufr5-RRt4nk7Qvy5wxVIIy7pU2gq6bFNYLKWNrUFCOOl3A8OR7zz5gKauoST6Z0tbYbsJPRDSZmBAM3cc0m4XSzGtMYl0U9qh_TLkQLLOov1NB75WfaRb3EEivfmsT0-iZY3PVWrZmiD-pLcnl-9vP0Ium3Xkic4GmbMGZznesgc5Ga4IDTcW29Z5yF4JQ1pTPALJ3SqQ5c-rIsAYeMQ9Mzl_rSZq_IQd3U_g2hqZPe6wClBCXgSaAgwluXBqWFLnkYkU8DFMVNp7BRgGWCwBURuAKBK3rgRuQE0do-ierY8UKz_FX0faQwknFnOFIjYCAe_21KfCN8hxRa8RH5MGBdwGjCXySm9s16VXDNcyA0OctH5HWH_fZVGZJVhbnVTq_YqcvuHejAUbF76LBv_z_rO_IY26Fb_TkkB-1y7d8DH2rtUVxHgPTrnEE6E-ooDog7xTgRrQ |
| link.rule.ids | 230,315,733,786,790,870,891,2115,4043,24346,27954,27955,27956,53825,53827 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKEYJLeZYuTyNxg2QT52lubdVqgW7FoRW9RbZjw0KTVLvJSuXv8EeZsZNtt-IClyRKYjuJP8vfODPfEPI2MKHikVBeqLLSiwWmeSk5DDzDpMiNBIqOwcnT43RyGn86S842SDrEwlinfSVnfn1e-fXsu_WtvKjUePATG3-Z7mN2oDDL8vEtchsGLEuuWek_HOuNoihxMTJgg_GxmVVVB9Ygi32Y4JLAMsqrecjK9f-NY950lbw29xzeJ1-Hp3YuJz_9rpW--nVD0PHfX-sB2erpKN111x-SDV0_IndcgsrLx-T3ASpMCHVJG0MXTYvrD5WQtKkpRjPPYb-367P3uI2pqEs8SOiik0uwwdHFxhYE49lTzdJjdLnwqY35ohqVlakL_wJr_QMV9EpVmrqIGltjpVvhiV47Bas7XylBU_RvfUJODw9O9iden9bBUzELWi8MZcpTbrI0DoRRwBcZl1qHLDRG5VKUSgBrVTkPuGGZLssyg95k0KmhCnQpo22yWTe13iE0UJnW3EAtJo_hTqA3sZYqMDmPecnMiLwbOrm4cOodBVg9CInCQqJASBQ9JEZkD3GwuhOVt-2JZv6t6DuqEFnIlGBIu4DdaPxvmmGL8B5ZzHM2Im8GFBUwUvH3i6h10y0KxlkKZCkN0xF56lC1aipCIpxj6XwNb2vPsn4FUGTVwAfUPPv_oq_J3cnJ9Kg4-nj8-Tm5h9_ErTK9IJvtvNMvgXe18pUdZH8Agn0xGg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLagCMSFfRlWI3GDbE4mjrm1paOytOqBSpU4RF5hoElGk2Sk8nf4o7yXZdqpOPWSRInt2PFn-XvOe58JeRu6SItYai_S3HiJxG1ejICB55iSmVNA0TE4-eAw3T9OPp9MTwavynpwqyy1mvvlaeGX85-db-Wi0MHoJxYcHezi7kAR51mwMC64Tm7AoGX8gqX-q2e-cRxP-zgZsMNE4OZF0YJFyBIfJrlp2LHK87mok-z_H8-87C55Yf6Z3SXfx5r3bie__bZRvv5zSdTxak27R-4MtJRu92nuk2u2fEBu9htVnj0kf_dQaULqM1o5WlcNrkMUUtGqpBjVvITzzrbP3uMxobI0eDGldatWYIujq02XEYxoT1crj9FV7dMu9otaVFimfRgYWO0fqKTn6tK0j6zpSixsIz05aKhgcadrRWiKfq6PyPFs79vuvjds7-DphIWNF0UqFalwPE1C6TTwRiaUtRGLnNOZkkZLYK86E6FwjFtjDIceZdCxkQ6tUfFjslVWpX1KaKi5tcJBKS5LICXQnMQqHbpMJMIwNyHvxo7OF72KRw7WD8Ii72CRIyzyARYTsoNYWKdEBe7uRrX8kQ-dlUseMS0Z0i9gORb_n3J8I7SDJyJjE_JmRFIOIxZ_w8jSVm2dM8FSIE1plE7Ikx5Z61fFSIgzzJ1tYG6jLptPAEmdKviInGdXz_qa3Dr6OMu_fjr88pzcxk_SLza9IFvNsrUvgX416lU3zv4B78gzmg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+sotrovimab+on+omicron+BA.2%2C+BA.4+and+BA.5+subvariants+of+sars-cov-2+vs.+other+early+therapies%3A+a+systematic+review+and+meta-analysis+of+literature+data&rft.jtitle=Frontiers+in+immunology&rft.au=Russo%2C+Antonio&rft.au=Grimaldi%2C+Pierantonio&rft.au=Pisaturo%2C+Mariantonietta&rft.au=Onorato%2C+Lorenzo&rft.date=2024&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=15&rft_id=info:doi/10.3389%2Ffimmu.2024.1295029&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fimmu_2024_1295029 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |